Healthcare
VivoSim Labs, Inc.(VIVS)
Live Price
Offline$1.10
-2.65% today
1Y Change
-25.17%
Window
Jun 23, 2025 → Jun 18, 2026
- Market Cap
- —
- Revenue Growth
- +32.1%
- EPS Growth
- +91.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VivoSim Labs, Inc. (VIVS) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.10 and down 25.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +32.1%, EPS growth of +91.2%, a dividend yield of 0.0%. What stands out right now is revenue +32.1%, EPS +91.2%, free cash flow +35.5% with operating margin -8066.2% and ROIC -228.3%. Valuation already assumes a fairly strong business story at price/sales 26.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VIVS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+32.1% vs +7.6% peer median
Operating Margin
Below sector median
-8066.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +32.1% and EPS at +91.2%, with operating margin around -8066.2%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VIVS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VIVS Max Drawdown
-76.99%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VIVS and SPY.
Company Overview
VivoSim Labs, Inc.
NASDAQ Global Market
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.
- Leadership
- Keith E. Murphy
- IPO Date
- Feb 14, 2012
- Employees
- 14
- Street Address
- 11555 Sorrento Valley Road
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 224 1000
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 26.4
- Price/Book
- 0.5
Growth
- Revenue
- +32.1%
- EPS
- +91.2%
- Free Cash Flow
- +35.5%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -8066.2%
- Net Margin
- -864.1%
- ROE
- -15.6%
- ROIC
- -228.3%
Balance Sheet
- Debt/Equity
- 0.13
- Current Ratio
- 2.44
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.